首页 > 最新文献

Communicable diseases intelligence (2018)最新文献

英文 中文
Erratum: Meningococcal Surveillance Australia: Reporting period 1 April to 30 June 2024. 更正:澳大利亚脑膜炎球菌监测:报告期为2024年4月1日至6月30日。
Q3 Medicine Pub Date : 2025-01-22 DOI: 10.33321/cdi.2025.49.008
Monica M Lahra, Sonya Natasha Hutabarat, Sebastiaan van Hal, Tiffany R Hogan

Abstract: Erratum to Commun Dis Intell (2018) 2024;48. (doi: 10.33321/cdi.2024.48.54).

摘要:《公共情报勘误》(2018)2024;48。(doi: 10.33321 / cdi.2024.48.54)。
{"title":"Erratum: Meningococcal Surveillance Australia: Reporting period 1 April to 30 June 2024.","authors":"Monica M Lahra, Sonya Natasha Hutabarat, Sebastiaan van Hal, Tiffany R Hogan","doi":"10.33321/cdi.2025.49.008","DOIUrl":"https://doi.org/10.33321/cdi.2025.49.008","url":null,"abstract":"<p><strong>Abstract: </strong>Erratum to <i>Commun Dis Intell (2018)</i> 2024;48. (doi: 10.33321/cdi.2024.48.54).</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"49 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Surveillance Outcome Program (AESOP) Bloodstream Infection Annual Report 2023. 澳大利亚抗微生物药物耐药性小组(琼脂)澳大利亚肠球菌监测结果计划(AESOP)血液感染年度报告2023。
Q3 Medicine Pub Date : 2024-12-18 DOI: 10.33321/cdi.2024.48.56
Geoffrey W Coombs, Denise A Daley, Princy Shoby, Auriane Form, Shakeel Mowlaboccus

Abstract: From 1 January to 31 December 2023, fifty-six institutions across Australia participated in the Australian Enterococcal Surveillance Outcome Program (AESOP). The aim of AESOP 2023 was to determine the proportion of enterococcal bacteraemia isolates in Australia that were antimicrobial resistant, and to determine the Enterococcus faecium molecular epidemiology. Of the 1,599 unique episodes of enterococcal bacteraemia investigated, 92.9% were caused by either E. faecalis (51.8%) or E. faecium (41.1%). Ampicillin and vancomycin resistance were not detected in E. faecalis but were detected in 94.2% and 50.8% of E. faecium respectively. Two linezolid-resistant E. faecalis were identified in 2023. Both isolates had linezolid minimum inhibitory concentrations (MICs) of 6.0 mg/L, were vancomycin susceptible, and harboured the optrA gene. Overall, 53.2% of E. faecium harboured either the vanA or the vanB gene; of these, 27.3% harboured vanA, 72.1% harboured vanB, and 0.6% harboured vanA and vanB. The percentage of vancomycin-resistant E. faecium bacteraemia isolates in Australia remains substantially higher than that recorded in most European countries. The E. faecium isolates consisted of 58 multi-locus sequence types (STs); 85.7% of isolates were classified into seven major STs, each containing ten or more isolates. All major STs belonged to clonal complex (CC) 17, a global hospital-adapted polyclonal E. faecium CC. The major STs (ST78, ST1424, ST17, ST80, ST796, ST1421 and ST555) were found across most regions of Australia, with ST78 identified in all regions. Overall, 58.3% of isolates belonging to the seven major STs harboured the vanA or vanB gene. AESOP 2023 has shown that enterococcal bacteraemia episodes in Australia continues to be frequently caused by polyclonal ampicillin-resistant high-level gentamicin-resistant vanA- or vanB-positive E. faecium which have limited treatment options.

摘要:从2023年1月1日至12月31日,澳大利亚56家机构参加了澳大利亚肠球菌监测结果计划(AESOP)。AESOP 2023的目的是确定澳大利亚耐药肠球菌菌血症分离株的比例,并确定屎肠球菌的分子流行病学。在调查的1599例肠球菌菌血症中,92.9%由粪肠球菌(51.8%)或粪肠球菌(41.1%)引起。未检出氨苄西林和万古霉素耐药性,但检出率分别为94.2%和50.8%。在2023年发现了2只耐利奈唑胺的粪肠球菌。两株菌株利奈唑胺最低抑菌浓度(mic)均为6.0 mg/L,对万古霉素敏感,携带optrA基因。总体而言,53.2%的粪肠杆菌携带vanA或vanB基因;其中,27.3%为维纳港,72.1%为维纳港,0.6%为维纳港和维纳港。澳大利亚耐万古霉素的粪肠杆菌菌血症分离株的百分比仍然大大高于大多数欧洲国家的记录。分离的粪肠杆菌有58个多位点序列类型(STs);85.7%的菌株被划分为7个主要STs,每个STs含有10个或更多的菌株。所有主要STs都属于克隆复合体(CC) 17,这是一种全球医院适应的多克隆粪杆菌CC,主要STs (ST78、ST1424、ST17、ST80、ST796、ST1421和ST555)在澳大利亚大部分地区都被发现,其中ST78在所有地区都被发现。总体而言,属于7个主要STs的58.3%的分离株含有vanA或vanB基因。AESOP 2023显示,澳大利亚肠球菌菌血症事件仍然经常由多克隆耐氨苄西林高水平耐庆大霉素的vanA-或vanb阳性屎肠杆菌引起,治疗选择有限。
{"title":"Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Surveillance Outcome Program (AESOP) Bloodstream Infection Annual Report 2023.","authors":"Geoffrey W Coombs, Denise A Daley, Princy Shoby, Auriane Form, Shakeel Mowlaboccus","doi":"10.33321/cdi.2024.48.56","DOIUrl":"https://doi.org/10.33321/cdi.2024.48.56","url":null,"abstract":"<p><strong>Abstract: </strong>From 1 January to 31 December 2023, fifty-six institutions across Australia participated in the Australian Enterococcal Surveillance Outcome Program (AESOP). The aim of AESOP 2023 was to determine the proportion of enterococcal bacteraemia isolates in Australia that were antimicrobial resistant, and to determine the <i>Enterococcus faecium</i> molecular epidemiology. Of the 1,599 unique episodes of enterococcal bacteraemia investigated, 92.9% were caused by either <i>E. faecalis</i> (51.8%) or <i>E. faecium</i> (41.1%). Ampicillin and vancomycin resistance were not detected in <i>E. faecalis</i> but were detected in 94.2% and 50.8% of <i>E. faecium</i> respectively. Two linezolid-resistant <i>E. faecalis</i> were identified in 2023. Both isolates had linezolid minimum inhibitory concentrations (MICs) of 6.0 mg/L, were vancomycin susceptible, and harboured the <i>optrA</i> gene. Overall, 53.2% of <i>E. faecium</i> harboured either the <i>vanA</i> or the <i>vanB</i> gene; of these, 27.3% harboured <i>vanA</i>, 72.1% harboured <i>vanB</i>, and 0.6% harboured <i>vanA</i> and <i>vanB</i>. The percentage of vancomycin-resistant <i>E. faecium</i> bacteraemia isolates in Australia remains substantially higher than that recorded in most European countries. The <i>E. faecium</i> isolates consisted of 58 multi-locus sequence types (STs); 85.7% of isolates were classified into seven major STs, each containing ten or more isolates. All major STs belonged to clonal complex (CC) 17, a global hospital-adapted polyclonal <i>E. faecium</i> CC. The major STs (ST78, ST1424, ST17, ST80, ST796, ST1421 and ST555) were found across most regions of Australia, with ST78 identified in all regions. Overall, 58.3% of isolates belonging to the seven major STs harboured the <i>vanA</i> or <i>vanB</i> gene. AESOP 2023 has shown that enterococcal bacteraemia episodes in Australia continues to be frequently caused by polyclonal ampicillin-resistant high-level gentamicin-resistant <i>vanA</i>- or <i>vanB</i>-positive <i>E. faecium</i> which have limited treatment options.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"48 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Surveillance Outcome Program (ASSOP) Bloodstream Infection Annual Report 2023. 澳大利亚抗菌药耐药性小组(AGAR)《澳大利亚金黄色葡萄球菌监测结果计划(ASSOP)2023 年血流感染年度报告》。
Q3 Medicine Pub Date : 2024-12-18 DOI: 10.33321/cdi.2024.48.57
Geoffrey W Coombs, Denise A Daley, Princy Shoby, Sruthi Mamoottil Sudeep, Shakeel Mowlaboccus
<p><strong>Abstract: </strong>From 1 January to 31 December 2023, fifty-seven institutions across Australia participated in the Australian <i>Staphylococcus aureus</i> Surveillance Outcome Program (ASSOP). The aim of ASSOP 2023 was to determine the proportion of <i>Staphylococcus aureus</i> bacteraemia (SAB) isolates in Australia that were antimicrobial resistant, with particular emphasis on methicillin resistance, and to characterise the methicillin-resistant <i>S. aureus</i> (MRSA) molecular epidemiology. A total of 3,422 SAB episodes were reported, of which 77.0% were community-onset. Overall, 16.1% of <i>S, aureus</i> were methicillin resistant. The 30-day all-cause mortality associated with methicillin-resistant SAB was 14.8%, which was not significantly different to the 16.5% all-cause mortality associated with methicillin-susceptible SAB (<i>p</i> = 0.44). With the exception of the β-lactams and erythromycin, antimicrobial resistance in methicillin-susceptible <i>S, aureus</i> (MSSA) was infrequent. However, in addition to the β-lactams, approximately 33% of MRSA were resistant to ciprofloxacin; 30% to erythromycin; 13% to tetracycline; 13% to gentamicin; and 3% to co-trimoxazole. Two New South Wales daptomycin-resistant MRSA, with minimum inhibitory concentrations (MICs) of 3.0 and 4.0 mg/L, were identified as ST22-IV, with a V351E <i>mprF</i> mutation, and ST45-V with a T345I <i>mprF</i> mutation respectively. Three daptomycin-resistant MSSA were identified. One from Tasmania, with a daptomycin MIC of 1.5 mg/L, identified as ST9295 with a L341I <i>mprF</i> mutation; one from New South Wales, with a daptomycin MIC of 3.0 mg/L, identified as ST97 with a L776S <i>mprF</i> mutation; and one from Western Australia, with a daptomycin MIC of 2.0 mg/L, identified as ST5. No previously reported mutations in known loci were detected in the Western Australian isolate. When applying the European Committee on Antimicrobial Susceptibility Testing breakpoints, teicoplanin resistance was detected in three MSSA isolates and one MRSA isolate. Vancomycin or linezolid resistance was not detected. Resistance to non-β-lactam antimicrobials was largely attributable to the healthcare-associated MRSA (HA-MRSA) clone ST22-IV [2B] (EMRSA-15), and the community-associated MRSA (CA-MRSA) clone ST45-V [5C2&5] which has acquired resistance to multiple antimicrobials including ciprofloxacin, clindamycin, erythromycin, gentamicin, and tetracycline. ST22-IV [2B] (EMRSA-15) was the predominant HA-MRSA clone in Australia. Overall, 85% of methicillin-resistant SAB were caused by community-associated MRSA (CA-MRSA) clones. Although polyclonal, approximately 70.3% of CA-MRSA clones were characterised as ST93-IV [2B] (Queensland clone); ST5-IV [2B]; ST1-IV [2B]; ST45-V [5C2&5]; ST30-IV [2B]; ST8-IV [2B]; ST6-IV [2B]; ST97-IV [2B]; and ST953-IV [2B]. As CA-MRSA is well established in the Australian community, it is important to monitor antimicrobial resistance patterns in commu
摘要:从2023年1月1日至12月31日,澳大利亚57家机构参加了澳大利亚金黄色葡萄球菌监测结果项目(ASSOP)。ASSOP 2023的目的是确定澳大利亚耐药金黄色葡萄球菌菌血症(SAB)分离株的比例,特别强调对甲氧西林的耐药性,并表征耐甲氧西林金黄色葡萄球菌(MRSA)的分子流行病学特征。总共报告了3422例SAB发作,其中77.0%为社区发病。总体而言,16.1%的金黄色葡萄球菌耐甲氧西林。耐甲氧西林SAB的30天全因死亡率为14.8%,与甲氧西林敏感SAB的16.5%无显著差异(p = 0.44)。除β-内酰胺类和红霉素外,甲氧西林敏感金黄色葡萄球菌(MSSA)的耐药情况罕见。然而,除了β-内酰胺外,约33%的MRSA对环丙沙星耐药;红霉素占30%;13%为四环素;庆大霉素占13%;3%的复方新诺明。鉴定出两种新南威尔士州达托霉素耐药MRSA,其最低抑制浓度(mic)分别为3.0和4.0 mg/L,分别为ST22-IV,突变为V351E mprF, ST45-V突变为T345I mprF。鉴定出3例耐达托霉素MSSA。一个来自塔斯马尼亚,达托霉素MIC为1.5 mg/L,鉴定为ST9295,携带L341I mprF突变;一株来自新南威尔士州,达托霉素MIC为3.0 mg/L,鉴定为ST97,携带L776S mprF突变;1例来自西澳大利亚,达托霉素MIC为2.0 mg/L,鉴定为ST5。在西澳大利亚分离株中未发现先前报道的已知位点突变。当应用欧洲抗微生物药物敏感性试验委员会的断点时,在3株MSSA分离株和1株MRSA分离株中检测到替柯普兰耐药。未检出万古霉素或利奈唑胺耐药。对非β-内酰胺类抗菌素的耐药性主要归因于医疗相关MRSA (HA-MRSA)克隆ST22-IV [2B] (EMRSA-15)和社区相关MRSA (CA-MRSA)克隆ST45-V [5C2&5],后者对环丙沙星、克林霉素、红霉素、庆大霉素和四环素等多种抗菌素产生耐药性。ST22-IV [2B] (EMRSA-15)是澳大利亚主要的HA-MRSA克隆。总体而言,85%的耐甲氧西林SAB是由社区相关的MRSA (CA-MRSA)克隆引起的。虽然是多克隆的,但大约70.3%的CA-MRSA克隆被鉴定为ST93-IV [2B](昆士兰克隆);ST5-IV (2 b);ST1-IV (2 b);ST45-V [5 c2&5];ST30-IV (2 b);ST8-IV (2 b);ST6-IV (2 b);ST97-IV (2 b);ST953-IV [2B]。由于CA-MRSA在澳大利亚社区已经建立,因此监测社区和医疗保健相关SAB的抗菌素耐药性模式非常重要,因为这些信息将指导治疗金黄色葡萄球菌血症的治疗实践。
{"title":"Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Surveillance Outcome Program (ASSOP) Bloodstream Infection Annual Report 2023.","authors":"Geoffrey W Coombs, Denise A Daley, Princy Shoby, Sruthi Mamoottil Sudeep, Shakeel Mowlaboccus","doi":"10.33321/cdi.2024.48.57","DOIUrl":"https://doi.org/10.33321/cdi.2024.48.57","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Abstract: &lt;/strong&gt;From 1 January to 31 December 2023, fifty-seven institutions across Australia participated in the Australian &lt;i&gt;Staphylococcus aureus&lt;/i&gt; Surveillance Outcome Program (ASSOP). The aim of ASSOP 2023 was to determine the proportion of &lt;i&gt;Staphylococcus aureus&lt;/i&gt; bacteraemia (SAB) isolates in Australia that were antimicrobial resistant, with particular emphasis on methicillin resistance, and to characterise the methicillin-resistant &lt;i&gt;S. aureus&lt;/i&gt; (MRSA) molecular epidemiology. A total of 3,422 SAB episodes were reported, of which 77.0% were community-onset. Overall, 16.1% of &lt;i&gt;S, aureus&lt;/i&gt; were methicillin resistant. The 30-day all-cause mortality associated with methicillin-resistant SAB was 14.8%, which was not significantly different to the 16.5% all-cause mortality associated with methicillin-susceptible SAB (&lt;i&gt;p&lt;/i&gt; = 0.44). With the exception of the β-lactams and erythromycin, antimicrobial resistance in methicillin-susceptible &lt;i&gt;S, aureus&lt;/i&gt; (MSSA) was infrequent. However, in addition to the β-lactams, approximately 33% of MRSA were resistant to ciprofloxacin; 30% to erythromycin; 13% to tetracycline; 13% to gentamicin; and 3% to co-trimoxazole. Two New South Wales daptomycin-resistant MRSA, with minimum inhibitory concentrations (MICs) of 3.0 and 4.0 mg/L, were identified as ST22-IV, with a V351E &lt;i&gt;mprF&lt;/i&gt; mutation, and ST45-V with a T345I &lt;i&gt;mprF&lt;/i&gt; mutation respectively. Three daptomycin-resistant MSSA were identified. One from Tasmania, with a daptomycin MIC of 1.5 mg/L, identified as ST9295 with a L341I &lt;i&gt;mprF&lt;/i&gt; mutation; one from New South Wales, with a daptomycin MIC of 3.0 mg/L, identified as ST97 with a L776S &lt;i&gt;mprF&lt;/i&gt; mutation; and one from Western Australia, with a daptomycin MIC of 2.0 mg/L, identified as ST5. No previously reported mutations in known loci were detected in the Western Australian isolate. When applying the European Committee on Antimicrobial Susceptibility Testing breakpoints, teicoplanin resistance was detected in three MSSA isolates and one MRSA isolate. Vancomycin or linezolid resistance was not detected. Resistance to non-β-lactam antimicrobials was largely attributable to the healthcare-associated MRSA (HA-MRSA) clone ST22-IV [2B] (EMRSA-15), and the community-associated MRSA (CA-MRSA) clone ST45-V [5C2&5] which has acquired resistance to multiple antimicrobials including ciprofloxacin, clindamycin, erythromycin, gentamicin, and tetracycline. ST22-IV [2B] (EMRSA-15) was the predominant HA-MRSA clone in Australia. Overall, 85% of methicillin-resistant SAB were caused by community-associated MRSA (CA-MRSA) clones. Although polyclonal, approximately 70.3% of CA-MRSA clones were characterised as ST93-IV [2B] (Queensland clone); ST5-IV [2B]; ST1-IV [2B]; ST45-V [5C2&5]; ST30-IV [2B]; ST8-IV [2B]; ST6-IV [2B]; ST97-IV [2B]; and ST953-IV [2B]. As CA-MRSA is well established in the Australian community, it is important to monitor antimicrobial resistance patterns in commu","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"48 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An outbreak of dengue virus type 3 on Mer Island in the Torres Strait, Australia in 2024. 2024 年澳大利亚托雷斯海峡默尔岛爆发 3 型登革热病毒。
Q3 Medicine Pub Date : 2024-12-18 DOI: 10.33321/cdi.2024.48.63
A Hempenstall, A Pyke, C Taunton, U Sabatino, S Kaigey, E Pickering, G Ehlers, M O Muzari, J Davis, C Paton, C Taylor, A van den Hurk, G Hewitson, S Schlebusch, J Hanson

Abstract: In early 2024, there were eight confirmed cases of locally acquired dengue on Mer Island in the Torres Strait. This dengue outbreak prompted an in-community public health response which included active case finding, health promotion and vector control. This was the first detected dengue outbreak in the Torres Strait since 2017. It highlights the importance of testing in primary healthcare, vector control and ongoing public health surveillance to minimise the risk of local transmission and establishment of endemic viruses which may cause significant and potentially life-threatening disease within populations in northern Australia.

摘要:2024年初,托雷斯海峡梅尔岛出现8例本地获得性登革热确诊病例。这次登革热疫情促使社区内采取了公共卫生应对措施,包括积极发现病例、促进健康和媒介控制。这是自2017年以来托雷斯海峡首次发现登革热疫情。它强调了在初级保健、病媒控制和持续的公共卫生监测中进行检测的重要性,以尽量减少地方传播和建立可能在澳大利亚北部人口中造成严重和可能危及生命的疾病的地方性病毒的风险。
{"title":"An outbreak of dengue virus type 3 on Mer Island in the Torres Strait, Australia in 2024.","authors":"A Hempenstall, A Pyke, C Taunton, U Sabatino, S Kaigey, E Pickering, G Ehlers, M O Muzari, J Davis, C Paton, C Taylor, A van den Hurk, G Hewitson, S Schlebusch, J Hanson","doi":"10.33321/cdi.2024.48.63","DOIUrl":"https://doi.org/10.33321/cdi.2024.48.63","url":null,"abstract":"<p><strong>Abstract: </strong>In early 2024, there were eight confirmed cases of locally acquired dengue on Mer Island in the Torres Strait. This dengue outbreak prompted an in-community public health response which included active case finding, health promotion and vector control. This was the first detected dengue outbreak in the Torres Strait since 2017. It highlights the importance of testing in primary healthcare, vector control and ongoing public health surveillance to minimise the risk of local transmission and establishment of endemic viruses which may cause significant and potentially life-threatening disease within populations in northern Australia.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"48 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Australian Meningococcal Surveillance Programme Annual Report, 2023. 澳大利亚脑膜炎球菌监测计划年度报告,2023年。
Q3 Medicine Pub Date : 2024-12-18 DOI: 10.33321/cdi.2024.48.52
Monica M Lahra, C R Robert George, Sebastiaan van Hal, Tiffany R Hogan

Abstract: In Australia, both probable and laboratory-confirmed cases of invasive meningococcal disease (IMD) are reported to the National Notifiable Diseases Surveillance System (NNDSS). When compared to 2022, the number of IMD notifications in 2023 increased by 14% to 143. Laboratory confirmation of IMD occurred in 140/143 (98%) of these cases, with 64% (90/140) diagnosed by bacterial culture and 36% (50/140) by nucleic acid amplification testing. The serogroup was determined for 96% of laboratory-confirmed cases (134/140): serogroup B (MenB) accounted for 84% of infections (112/134); MenW for 8% (11/134); MenY for 8% (11/134). There were no infections attributed to MenC disease. Fine typing was available on 75% of the cases for which the serogroup was determined (100/134). In MenB isolates, 25 porA types were detected, the most prevalent of which were P1.7-2,4 (32%; 26/82), P1.7,16-26 (16%; 13/82) and P1.22,14 (9%; 7/82). All eight typed MenW infections identified as porA type P1.5,2, with two different multi-locus sequence types (MLST) present: ST-11 (5) and ST-1287 (3) from the clonal complex 11, the hypervirulent strain reported in outbreaks in Australia and overseas. In MenY, the predominant porA type was P1.5-1,10-1 (90%; 9/10), ST-1655 and from clonal complex 23. Peaks of IMD occurred in children aged less than 5 years and in those aged 15-24 years, accounting for 21% (30/140) and 26% (37/140) of laboratory-confirmed cases respectively. In children aged under 5 years, 93% of IMD (27/29) was MenB; in those aged 15-24 years, 97% of IMD (36/37) was MenB, with serogroup not determined for one case in each of these age groups. Of note, 14-15% of IMD occurred in each of the older age groups reported: adults 25-44 years (14%, 19/140), 45-64 years (14%, 20/140), and in those aged 65 years and older (15%, 21/140). Whilst MenB predominated in all age groups, the majority of MenY and MenW IMD cases were reported in adults aged 45 years and older. All cultured IMD isolates (n = 90) had antimicrobial susceptibility testing performed. Minimum inhibitory concentration (MIC) values were reported using Clinical Laboratory Standards Institute (CLSI) interpretative criteria: 9% (8/90) were defined as penicillin resistant (MIC value: ≥ 0.5 mg/L); 71% (64/90) had intermediate susceptibility to penicillin (MIC values: 0.125 and 0.25 mg/L) and 20% (18/90) were susceptible to penicillin (MIC values: ≤ 0.064 mg/L). All isolates tested susceptible to ceftriaxone, ciprofloxacin and rifampicin.

摘要:在澳大利亚,侵袭性脑膜炎球菌病(IMD)的可能病例和实验室确诊病例均向国家法定疾病监测系统(NNDSS)报告。与2022年相比,2023年的IMD通知数量增加了14%,达到143份。这些病例中有140/143例(98%)确诊为IMD,其中64%(90/140)通过细菌培养诊断,36%(50/140)通过核酸扩增检测诊断。96%的实验室确诊病例(134/140)确定了血清型;84%的感染病例(112/134)确定了血清B型(MenB);男性占8% (11/134);价格为8%(11/134)。没有感染归因于MenC病。在确定血清组的病例中,75%(100/134)可进行精细分型。在MenB分离株中检出25种孔a型,其中以p1.7 ~ 2,4 (32%;26/82), p1.7,16-26 (16%;13/82)和P1.22,14 (9%;7/82)。所有8型MenW感染均被鉴定为P1.5,2型porA型,存在两种不同的多位点序列型(MLST): ST-11(5)和ST-1287(3),来自克隆复合体11,澳大利亚和海外暴发的高毒菌株。在MenY,主要的porA类型为P1.5-1,10-1 (90%;9/10), ST-1655,克隆配合物23。5岁以下儿童和15-24岁儿童是IMD的发病高峰,分别占实验室确诊病例的21%(30/140)和26%(37/140)。在5岁以下儿童中,93%的IMD(27/29)是MenB;在15-24岁的人群中,97%的IMD(36/37)是MenB,每个年龄组中有1例未确定血清组。值得注意的是,14-15%的IMD发生在报告的每个较大年龄组:25-44岁的成年人(14%,19/140),45-64岁的成年人(14%,20/140)和65岁及以上的老年人(15%,21/140)。虽然MenB在所有年龄组中占主导地位,但大多数MenY和MenW型IMD病例报告发生在45岁及以上的成年人中。所有培养的IMD分离株(n = 90)均进行了抗菌药敏试验。根据临床实验室标准协会(CLSI)的解释标准报告最低抑菌浓度(MIC)值:9%(8/90)被定义为青霉素耐药(MIC值:≥0.5 mg/L);71%(64/90)对青霉素有中等敏感性(MIC值分别为0.125和0.25 mg/L), 20%(18/90)对青霉素敏感(MIC值≤0.064 mg/L)。所有分离株均对头孢曲松、环丙沙星和利福平敏感。
{"title":"Australian Meningococcal Surveillance Programme Annual Report, 2023.","authors":"Monica M Lahra, C R Robert George, Sebastiaan van Hal, Tiffany R Hogan","doi":"10.33321/cdi.2024.48.52","DOIUrl":"https://doi.org/10.33321/cdi.2024.48.52","url":null,"abstract":"<p><strong>Abstract: </strong>In Australia, both probable and laboratory-confirmed cases of invasive meningococcal disease (IMD) are reported to the National Notifiable Diseases Surveillance System (NNDSS). When compared to 2022, the number of IMD notifications in 2023 increased by 14% to 143. Laboratory confirmation of IMD occurred in 140/143 (98%) of these cases, with 64% (90/140) diagnosed by bacterial culture and 36% (50/140) by nucleic acid amplification testing. The serogroup was determined for 96% of laboratory-confirmed cases (134/140): serogroup B (MenB) accounted for 84% of infections (112/134); MenW for 8% (11/134); MenY for 8% (11/134). There were no infections attributed to MenC disease. Fine typing was available on 75% of the cases for which the serogroup was determined (100/134). In MenB isolates, 25 <i>porA</i> types were detected, the most prevalent of which were P1.7-2,4 (32%; 26/82), P1.7,16-26 (16%; 13/82) and P1.22,14 (9%; 7/82). All eight typed MenW infections identified as <i>porA</i> type P1.5,2, with two different multi-locus sequence types (MLST) present: ST-11 (5) and ST-1287 (3) from the clonal complex 11, the hypervirulent strain reported in outbreaks in Australia and overseas. In MenY, the predominant <i>porA</i> type was P1.5-1,10-1 (90%; 9/10), ST-1655 and from clonal complex 23. Peaks of IMD occurred in children aged less than 5 years and in those aged 15-24 years, accounting for 21% (30/140) and 26% (37/140) of laboratory-confirmed cases respectively. In children aged under 5 years, 93% of IMD (27/29) was MenB; in those aged 15-24 years, 97% of IMD (36/37) was MenB, with serogroup not determined for one case in each of these age groups. Of note, 14-15% of IMD occurred in each of the older age groups reported: adults 25-44 years (14%, 19/140), 45-64 years (14%, 20/140), and in those aged 65 years and older (15%, 21/140). Whilst MenB predominated in all age groups, the majority of MenY and MenW IMD cases were reported in adults aged 45 years and older. All cultured IMD isolates (n = 90) had antimicrobial susceptibility testing performed. Minimum inhibitory concentration (MIC) values were reported using Clinical Laboratory Standards Institute (CLSI) interpretative criteria: 9% (8/90) were defined as penicillin resistant (MIC value: ≥ 0.5 mg/L); 71% (64/90) had intermediate susceptibility to penicillin (MIC values: 0.125 and 0.25 mg/L) and 20% (18/90) were susceptible to penicillin (MIC values: ≤ 0.064 mg/L). All isolates tested susceptible to ceftriaxone, ciprofloxacin and rifampicin.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"48 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Measles secondary vaccine failure in a childcare setting: an outbreak report. 儿童保育机构麻疹二次疫苗接种失败:疫情报告。
Q3 Medicine Pub Date : 2024-11-21 DOI: 10.33321/cdi.2024.48.61
Donna Barnekow, Debbie Neucom, Wendy Tout, Dustylee Williams, Michael J Thomas, Sanmarié Schlebusch, Alyssa Pyke, Madisen S Roser, Isaac Tranter, Amalie Dyda, Colleen L Lau, Nicolas R Smoll

Abstract: The Sunshine Coast Public Health Unit (SCPHU) identified a measles case in a childcare educator (CE) with secondary vaccine failure (SVF). The CE had been exposed to a confirmed measles case in a hospital emergency department and later developed symptoms including fever, cough, malaise, and a rash. Diagnostic tests confirmed measles virus infection. Sunshine Coast Public Health Unit (SCPHU) implemented control measures including contact tracing, vaccination, post-exposure prophylaxis, and quarantine for susceptible contacts. Out of 372 identified contacts, 72 were identified as susceptible, all of whom were infants and children. Despite the CE having close contact to all susceptible infants and children, no onward transmission occurred. This suggests that SVF cases pose a lower risk of spreading measles compared to immunologically naïve individuals. This report highlights the importance of prioritising immunologically naïve cases in outbreak responses.

摘要:阳光海岸公共卫生股(SCPHU)发现一名儿童保育员(CE)感染了麻疹病例,并伴有继发性疫苗接种失败(SVF)。该儿童保育员曾在医院急诊科接触过一例麻疹确诊病例,随后出现发烧、咳嗽、不适和皮疹等症状。诊断检测证实他感染了麻疹病毒。阳光海岸公共卫生股(SCPHU)采取了控制措施,包括追踪接触者、接种疫苗、接触后预防以及对易感接触者进行隔离。在已确认的 372 名接触者中,有 72 人被确认为易感人群,他们都是婴幼儿。尽管行政长官与所有易感婴幼儿都有密切接触,但并未发生继续传播。这表明,与免疫力低下的人相比,SVF 病例传播麻疹的风险较低。这份报告强调了在应对疫情时优先考虑免疫力低下病例的重要性。
{"title":"Measles secondary vaccine failure in a childcare setting: an outbreak report.","authors":"Donna Barnekow, Debbie Neucom, Wendy Tout, Dustylee Williams, Michael J Thomas, Sanmarié Schlebusch, Alyssa Pyke, Madisen S Roser, Isaac Tranter, Amalie Dyda, Colleen L Lau, Nicolas R Smoll","doi":"10.33321/cdi.2024.48.61","DOIUrl":"https://doi.org/10.33321/cdi.2024.48.61","url":null,"abstract":"<p><strong>Abstract: </strong>The Sunshine Coast Public Health Unit (SCPHU) identified a measles case in a childcare educator (CE) with secondary vaccine failure (SVF). The CE had been exposed to a confirmed measles case in a hospital emergency department and later developed symptoms including fever, cough, malaise, and a rash. Diagnostic tests confirmed measles virus infection. Sunshine Coast Public Health Unit (SCPHU) implemented control measures including contact tracing, vaccination, post-exposure prophylaxis, and quarantine for susceptible contacts. Out of 372 identified contacts, 72 were identified as susceptible, all of whom were infants and children. Despite the CE having close contact to all susceptible infants and children, no onward transmission occurred. This suggests that SVF cases pose a lower risk of spreading measles compared to immunologically naïve individuals. This report highlights the importance of prioritising immunologically naïve cases in outbreak responses.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"48 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142682502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Meningococcal Surveillance Australia: Reporting period 1 April to 30 June 2024. 澳大利亚脑膜炎球菌监测:报告期为 2024 年 4 月 1 日至 6 月 30 日。
Q3 Medicine Pub Date : 2024-11-21 DOI: 10.33321/cdi.2024.48.54
Monica M Lahra, Sonya Natasha Hutabarat, Tiffany R Hogan

Abstract: The reference laboratories of the Australian Meningococcal Surveillance Programme (AMSP) report data on the number of cases of invasive meningococcal disease (IMD) confirmed by laboratory testing using culture and molecular based techniques. Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known and expanded in 2024 to include antimicrobial resistance data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. A full analysis of laboratory confirmations of IMD in each calendar year is contained in the AMSP annual reports.

摘要:澳大利亚脑膜炎球菌监测计划(AMSP)的参考实验室利用培养和分子技术报告经实验室检测确诊的侵袭性脑膜炎球菌病(IMD)病例数数据。季度报告中的数据仅限于按辖区和血清群(如果已知)描述侵袭性脑膜炎球菌病病例数,并在 2024 年扩展到包括头孢曲松、青霉素、环丙沙星和利福平的抗菌药耐药性数据。AMSP 年度报告中载有对每个日历年 IMD 实验室确诊情况的全面分析。
{"title":"Meningococcal Surveillance Australia: Reporting period 1 April to 30 June 2024.","authors":"Monica M Lahra, Sonya Natasha Hutabarat, Tiffany R Hogan","doi":"10.33321/cdi.2024.48.54","DOIUrl":"https://doi.org/10.33321/cdi.2024.48.54","url":null,"abstract":"<p><strong>Abstract: </strong>The reference laboratories of the Australian Meningococcal Surveillance Programme (AMSP) report data on the number of cases of invasive meningococcal disease (IMD) confirmed by laboratory testing using culture and molecular based techniques. Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known and expanded in 2024 to include antimicrobial resistance data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. A full analysis of laboratory confirmations of IMD in each calendar year is contained in the AMSP annual reports.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"48 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142682503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Never waste a measles outbreak. 切勿浪费麻疹疫情。
Q3 Medicine Pub Date : 2024-11-21 DOI: 10.33321/cdi.2024.48.62
David N Durrheim

Abstract: This editorial focuses on the instructive value of carefully investigated measles outbreaks with reference to the outbreak report, also published today in CDI (doi: /10.33321/cdi.2024.48.61), documenting an apparent measles secondary vaccine failure affecting a Sunshine Coast childcare facility with no ongoing transmission.

摘要:这篇社论的重点是仔细调查麻疹疫情的指导价值,并参考了今天也发表在《CDI》上的疫情报告(doi: /10.33321/cdi.2024.48.61),该报告记录了阳光海岸一家托儿所的麻疹二联疫苗明显失效,但没有持续传播。
{"title":"Never waste a measles outbreak.","authors":"David N Durrheim","doi":"10.33321/cdi.2024.48.62","DOIUrl":"https://doi.org/10.33321/cdi.2024.48.62","url":null,"abstract":"<p><strong>Abstract: </strong>This editorial focuses on the instructive value of carefully investigated measles outbreaks with reference to the outbreak report, also published today in CDI (doi: /10.33321/cdi.2024.48.61), documenting an apparent measles secondary vaccine failure affecting a Sunshine Coast childcare facility with no ongoing transmission.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"48 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142682777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Meningococcal Surveillance Australia: Reporting period 1 January to 31 March 2024. 澳大利亚脑膜炎球菌监测:报告期为 2024 年 1 月 1 日至 3 月 31 日。
Q3 Medicine Pub Date : 2024-11-21 DOI: 10.33321/cdi.2024.48.53
Monica M Lahra, Sonya Natasha Hutabarat, Tiffany R Hogan

Abstract: The reference laboratories of the Australian Meningococcal Surveillance Programme (AMSP) report data on the number of cases of invasive meningococcal disease (IMD) confirmed by laboratory testing using culture and molecular based techniques. Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known and expanded in 2024 to include antimicrobial resistance data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. A full analysis of laboratory confirmations of IMD in each calendar year is contained in the AMSP annual reports.

摘要:澳大利亚脑膜炎球菌监测计划(AMSP)的参考实验室利用培养和分子技术报告经实验室检测确诊的侵袭性脑膜炎球菌病(IMD)病例数数据。季度报告中的数据仅限于按辖区和血清群(如果已知)描述侵袭性脑膜炎球菌病病例数,并在 2024 年扩展到包括头孢曲松、青霉素、环丙沙星和利福平的抗菌药耐药性数据。AMSP 年度报告中载有对每个日历年 IMD 实验室确诊情况的全面分析。
{"title":"Meningococcal Surveillance Australia: Reporting period 1 January to 31 March 2024.","authors":"Monica M Lahra, Sonya Natasha Hutabarat, Tiffany R Hogan","doi":"10.33321/cdi.2024.48.53","DOIUrl":"https://doi.org/10.33321/cdi.2024.48.53","url":null,"abstract":"<p><strong>Abstract: </strong>The reference laboratories of the Australian Meningococcal Surveillance Programme (AMSP) report data on the number of cases of invasive meningococcal disease (IMD) confirmed by laboratory testing using culture and molecular based techniques. Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known and expanded in 2024 to include antimicrobial resistance data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. A full analysis of laboratory confirmations of IMD in each calendar year is contained in the AMSP annual reports.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"48 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142682776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fresh produce-associated foodborne disease outbreaks in Australia, 2001 to 2017. 2001年至2017年澳大利亚与新鲜农产品相关的食源性疾病暴发。
Q3 Medicine Pub Date : 2024-10-23 DOI: 10.33321/cdi.2024.48.19
Joanna G Rothwell, Rhiannon Wallace, Mark Bradbury, Laura Ford, Kathryn Glass, Robyn McConchie, Dee Carter, Martyn D Kirk

Abstract: Fresh produce is an important source of foodborne outbreaks in Australia. Using descriptive analysis, we examined confirmed and suspected foodborne outbreaks associated with fresh produce in Australia recorded in the OzFoodNet outbreak register from 2001 to 2017. The outbreak register contains reports of foodborne disease outbreaks collected by OzFoodNet epidemiologists and public health officials. A fresh produce outbreak was defined as the occurrence of two or more cases of the same illness in which the investigation had implicated a common food and this food contained fresh produce. A total of 92 fresh produce outbreaks were reported, encompassing 3,422 reported illnesses, 446 hospitalisations and four deaths. Of these outbreaks, 76.1% (70/92) were caused by a known pathogen, with the majority caused by either Salmonella enterica (n = 30) or Norovirus (n = 29). Most outbreaks (77.2%; 71/92) were associated with consumption of foods containing multiple ingredients, some of which were not fresh produce. The largest outbreaks associated with a single fresh produce item included bean sprouts contaminated with S. enterica serovar Saintpaul (419 illnesses and 76 hospitalisations) and semi-dried tomatoes contaminated with Hepatitis A (372 illnesses and 169 hospitalisations). Restaurants (45.7%; n = 42/92) and commercial catering (15.2%: n = 14/92) were common settings for fresh produce outbreaks. Outbreaks occurred in all states and territories of Australia and in all seasons, with an increased frequency in the warmer months (September-May). Although the number of fresh produce-associated outbreaks did not seem to be increasing in Australia, integrated surveillance is needed to rapidly identify sources of infection due to the propensity of these outbreaks to be large and widespread.

摘要:新鲜农产品是澳大利亚食源性疾病暴发的一个重要来源。通过描述性分析,我们研究了2001年至2017年OzFoodNet疫情登记册中记录的与澳大利亚新鲜农产品相关的确诊和疑似食源性疫情。疫情登记簿包含由 OzFoodNet 流行病学家和公共卫生官员收集的食源性疾病疫情报告。鲜活农产品疫情的定义是,发生两例或两例以上相同疾病的病例,且调查牵涉到一种常见食物,而这种食物中含有鲜活农产品。共报告了 92 起鲜活农产品疫情,涉及 3422 例报告病例、446 例住院病例和 4 例死亡病例。在这些暴发事件中,76.1%(70/92)是由已知病原体引起的,其中大多数是由肠炎沙门氏菌(30 例)或诺如病毒(29 例)引起的。大多数疫情(77.2%;71/92)与食用含有多种配料的食品有关,其中一些并非新鲜农产品。与单一新鲜农产品有关的最大疫情包括受圣帕氏杆菌污染的豆芽(419 例疾病和 76 例住院治疗)和受甲型肝炎污染的半干番茄(372 例疾病和 169 例住院治疗)。餐馆(45.7%;n = 42/92)和商业餐饮业(15.2%:n = 14/92)是新鲜农产品爆发的常见场所。疫情爆发发生在澳大利亚的所有州和地区以及所有季节,在温暖的月份(9 月至 5 月)爆发的频率更高。尽管澳大利亚与新鲜农产品相关的疫情爆发数量似乎没有增加,但由于这些疫情爆发的规模大、范围广,因此需要进行综合监测,以迅速确定感染源。
{"title":"Fresh produce-associated foodborne disease outbreaks in Australia, 2001 to 2017.","authors":"Joanna G Rothwell, Rhiannon Wallace, Mark Bradbury, Laura Ford, Kathryn Glass, Robyn McConchie, Dee Carter, Martyn D Kirk","doi":"10.33321/cdi.2024.48.19","DOIUrl":"https://doi.org/10.33321/cdi.2024.48.19","url":null,"abstract":"<p><strong>Abstract: </strong>Fresh produce is an important source of foodborne outbreaks in Australia. Using descriptive analysis, we examined confirmed and suspected foodborne outbreaks associated with fresh produce in Australia recorded in the OzFoodNet outbreak register from 2001 to 2017. The outbreak register contains reports of foodborne disease outbreaks collected by OzFoodNet epidemiologists and public health officials. A fresh produce outbreak was defined as the occurrence of two or more cases of the same illness in which the investigation had implicated a common food and this food contained fresh produce. A total of 92 fresh produce outbreaks were reported, encompassing 3,422 reported illnesses, 446 hospitalisations and four deaths. Of these outbreaks, 76.1% (70/92) were caused by a known pathogen, with the majority caused by either Salmonella enterica (n = 30) or Norovirus (n = 29). Most outbreaks (77.2%; 71/92) were associated with consumption of foods containing multiple ingredients, some of which were not fresh produce. The largest outbreaks associated with a single fresh produce item included bean sprouts contaminated with S. enterica serovar Saintpaul (419 illnesses and 76 hospitalisations) and semi-dried tomatoes contaminated with Hepatitis A (372 illnesses and 169 hospitalisations). Restaurants (45.7%; n = 42/92) and commercial catering (15.2%: n = 14/92) were common settings for fresh produce outbreaks. Outbreaks occurred in all states and territories of Australia and in all seasons, with an increased frequency in the warmer months (September-May). Although the number of fresh produce-associated outbreaks did not seem to be increasing in Australia, integrated surveillance is needed to rapidly identify sources of infection due to the propensity of these outbreaks to be large and widespread.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"48 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142509748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Communicable diseases intelligence (2018)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1